Possible mechanism for in vitro complement activation in blood and plasma samples: futhan/EDTA controls in vitro complement activation
Abstract
AbstractBackground: Ongoing in vitro complement (C) activation in citrate or EDTA plasma has prevented an accurate analysis of C-activation products generated in vivo. The aim of this study was to characterize handling and storage conditions required to prevent in vitro C activation in blood and plasma samples collected with Futhan/EDTA.Methods: BiotrakTM RIAs were used to quantitatively measure C3a and C4a in blood and/or plasma samples from healthy individuals (controls) and from liver transplant patients. Blood samples were routinely drawn into either EDTA (1 g/L) tubes or into tubes containing both EDTA (1 g/L) and Futhan (0.1 g/L) and immediately centrifuged at 2000g for 15 min at 4 °C.Results: In controls, C4a, but not C3a, in fresh samples (time 0) was higher in EDTA plasma than in Futhan/EDTA plasma (n = 20; P = 0.002). Futhan/EDTA prevented C3a and C4a generation in blood and plasma samples held at room temperature (22–23 °C) for 1 h and in plasma held for 24 h at 4 °C or −70 °C. The mean C3a concentration (1.76 mg/L; n = 19) at time 0 in EDTA plasma samples from liver transplant patients was significantly higher than for controls (0.34 mg/L; n = 11). In these patients, the mean C3a in EDTA samples increased to 13.8 mg/L after 60 min at room temperature, but there was no change in the C3a concentration of an EDTA plasma from a control. In the patients, C3a concentrations were lower in Futhan/EDTA plasma than in EDTA at time 0 and after 60 min at room temperature (1.40 and 2.02 mg/L, respectively). The mean patient C4a was 4.02 mg/L in EDTA plasma at time 0 vs 0.24 mg/L for controls; it increased to 16.9 mg/L after 60 min at room temperature compared with 0.76 mg/L for controls. The mean patient C4a was 0.83 mg/L in Futhan/EDTA plasma at time 0 vs 0.1 mg/L for controls. Neither patient nor control C4a concentrations increased vs time in Futhan/EDTA.Conclusion: The combination of Futhan (0.1 g/L) and EDTA (1 g/L) eliminates in vitro C activation.
Key Biomarkers
Cited By (3)
- Effect of C1-esterase-inhibitor on capillary leak and inflammatory response syndrome during arterial switch operations in neonatesJournal of Cardiothoracic and Vascular Anesthesia · 2001
- Complement activation in patients with primary antiphospholipid syndromeAnnals of the Rheumatic Diseases · 2009
- Plasma C3a and C4a levels in liver transplant recipients: a longitudinal studyImmunopharmacology · 2000
References (3)
- Circulating complement proteins in patients with sepsis or systemic inflammatory response syndromeClinical and Diagnostic Laboratory Immunology · 1996
- Anaphylatoxin generation in multisystem organ failureThe Journal of Trauma: Injury, Infection, and Critical Care · 1984
- Elevated plasma levels of the anaphylatoxins C3a and C4a are associated with a fatal outcome in sepsisThe American Journal of Medicine · 1989
Related Papers
- Pro-resolving and anti-arthritic properties of the MC1 selective agonist PL8177Frontiers in Immunology · 2022 · 1 shared tag
- Effects of Omega-3 Polyunsaturated Fatty Acids on the Formation of Adipokines, Cytokines, and Oxylipins in Retroperitoneal Adipose Tissue of MiceInternational Journal of Molecular Sciences · 2024 · 1 shared tag
- Fungal immunity and pathogenesis in mammals versus the invertebrate model organismGalleria mellonellaPathogens and Disease · 2021 · 1 shared tag
- TLR signaling pathway and the effects of main immune cells and epigenetics factors on the diagnosis and treatment of infertility and sterilityHeliyon · 2024 · 1 shared tag
- CGRP sensory neurons promote tissue healing via neutrophils and macrophagesNature · 2024 · 1 shared tag
- Invited review: Mechanisms of hypophagia during diseaseJournal of Dairy Science · 2021 · 1 shared tag